Ekso Bionics Stock to Reverse Split on Tuesday, May 27th (NASDAQ:EKSO)

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) are scheduled to reverse split before the market opens on Tuesday, May 27th. The 1-15 reverse split was announced on Monday, May 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, May 26th.

Ekso Bionics Trading Up 10.4%

Shares of EKSO stock opened at $0.28 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The company has a market cap of $9.83 million, a price-to-earnings ratio of -0.43 and a beta of 1.09. The stock has a 50 day simple moving average of $0.42 and a 200-day simple moving average of $0.55. Ekso Bionics has a 1-year low of $0.23 and a 1-year high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $4.62 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. On average, equities research analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EKSO. Lake Street Capital decreased their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. HC Wainwright reduced their target price on Ekso Bionics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Finally, Wall Street Zen initiated coverage on Ekso Bionics in a report on Thursday. They set a “hold” rating for the company.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Armistice Capital LLC lifted its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,042,382 shares of the company’s stock after buying an additional 316,733 shares during the period. Armistice Capital LLC owned approximately 7.03% of Ekso Bionics worth $823,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.